BAYER DIAGNOSTICS ADDS CEA ASSAY TO TECHNICON CANCER TEST PANEL WITH JAN. 30 PMA APPROVAL; THREE CA ASSAYS LICENSED FROM CENTOCOR IN FIRM'S PIPELINE
This article was originally published in The Gray Sheet
Executive Summary
Bayer Diagnostics added a second assay to its planned panel of six cancer tests on Jan. 30 with the approval of the Technicon Immuno 1 carcinoembryonic antigen (CEA) assay for monitoring cancer patients. The approval follows FDA clearance of the first test, a prostate specific antigen (PSA) assay, on Dec. 22.